These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16525633)

  • 1. Significance of Id-1 up-regulation and its association with EGFR in bladder cancer cell invasion.
    Ding Y; Wang G; Ling MT; Wong YC; Li X; Na Y; Zhang X; Chua CW; Wang X; Xin D
    Int J Oncol; 2006 Apr; 28(4):847-54. PubMed ID: 16525633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of Id-1 and its association with EGFR in renal cell cancer.
    Li X; Zhang Z; Xin D; Chua CW; Wong YC; Leung SC; Na Y; Wang X
    Histopathology; 2007 Mar; 50(4):484-90. PubMed ID: 17448024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel role of Id-1 in regulation of epithelial-to-mesenchymal transition in bladder cancer.
    Hu H; Wang YL; Wang GW; Wong YC; Wang XF; Wang Y; Xu KX
    Urol Oncol; 2013 Oct; 31(7):1242-53. PubMed ID: 22226665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Id protein interactions by an engineered HLH domain induces human neuroblastoma cell differentiation.
    Ciarapica R; Annibali D; Raimondi L; Savino M; Nasi S; Rota R
    Oncogene; 2009 Apr; 28(17):1881-91. PubMed ID: 19330020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process.
    Theodorescu D; Laderoute KR; Gulding KM
    Cell Growth Differ; 1998 Nov; 9(11):919-28. PubMed ID: 9831244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel function of Id-1 in mediating the anticancer responses of SAMC, a water-soluble garlic derivative, in human bladder cancer cells.
    Hu H; Zhang XP; Wang YL; Chua CW; Luk SU; Wong YC; Ling MT; Wang XF; Xu KX
    Mol Med Rep; 2011; 4(1):9-16. PubMed ID: 21461556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder.
    Wang X; Zhang S; MacLennan GT; Eble JN; Lopez-Beltran A; Yang XJ; Pan CX; Zhou H; Montironi R; Cheng L
    Clin Cancer Res; 2007 Feb; 13(3):953-7. PubMed ID: 17289890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment.
    Qu XJ; Yang JL; Russell PJ; Goldstein D
    J Urol; 2004 Aug; 172(2):733-8. PubMed ID: 15247772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.
    Schindl M; Schoppmann SF; Ströbel T; Heinzl H; Leisser C; Horvat R; Birner P
    Clin Cancer Res; 2003 Feb; 9(2):779-85. PubMed ID: 12576450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer.
    Cardillo MR; Castagna G; Memeo L; De Bernardinis E; Di Silverio F
    J Exp Clin Cancer Res; 2000 Jun; 19(2):225-33. PubMed ID: 10965823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA interference suppressing PLCE1 gene expression decreases invasive power of human bladder cancer T24 cell line.
    Ou L; Guo Y; Luo C; Wu X; Zhao Y; Cai X
    Cancer Genet Cytogenet; 2010 Jul; 200(2):110-9. PubMed ID: 20620593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
    Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
    Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
    Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
    Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
    Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
    Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing Id-1 with RNA interference inhibits adenoid cystic carcinoma in mice.
    Chen Z; Liu S; Sumida T; Sun S; Wei Y; Liu M; Dong Z; Zhang F; Hamakawa H; Wei F
    J Surg Res; 2011 Jul; 169(1):57-66. PubMed ID: 20189601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
    Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
    Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.
    Kawanishi H; Matsui Y; Ito M; Watanabe J; Takahashi T; Nishizawa K; Nishiyama H; Kamoto T; Mikami Y; Tanaka Y; Jung G; Akiyama H; Nobumasa H; Guilford P; Reeve A; Okuno Y; Tsujimoto G; Nakamura E; Ogawa O
    Clin Cancer Res; 2008 May; 14(9):2579-87. PubMed ID: 18451219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
    Cai CQ; Peng Y; Buckley MT; Wei J; Chen F; Liebes L; Gerald WL; Pincus MR; Osman I; Lee P
    Oncogene; 2008 May; 27(22):3201-10. PubMed ID: 18193092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87.
    Yang WM; Yan ZJ; Ye ZQ; Guo DS
    BJU Int; 2006 Oct; 98(4):898-902. PubMed ID: 16978290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.